It will be interesting to see how the FDA handles the rest of our products that will be very similar to ELI 200. One would think they would use common sense and realize that the ART technology has been thoroughly tested with ELI 200 and that the true question should be: are the next products bioequivalent to their competitors? It's quite obvious that opioids control pain. Do we really have to prove this 16 more times? Do generic opioids always require trials for approval?
News 
Market Data 
Discover 
